0000950170-24-040302.txt : 20240402 0000950170-24-040302.hdr.sgml : 20240402 20240402165850 ACCESSION NUMBER: 0000950170-24-040302 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Roth David CENTRAL INDEX KEY: 0001599014 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 24815297 MAIL ADDRESS: STREET 1: C/O SYROS PHARMACEUTICALS, INC. STREET 2: 620 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 4 1 ownership.xml 4 X0508 4 2024-03-31 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001599014 Roth David C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 false true false false Chief Medical Officer true Common Stock 2024-03-31 4 M false 2000 A 2000 D Common Stock 2024-03-31 4 M false 13333 A 15333 D Common Stock 2024-04-01 4 F false 4732 5.12 D 10601 D Common Stock 2024-04-02 4 S false 150 4.9803 D 10451 D Restricted Stock Units 2024-03-31 4 M false 2000 0.00 D Common Stock 2000 4000 D Restricted Stock Units 2024-03-31 4 M false 13333 0.00 D Common Stock 13333 26667 D Represents shares of common stock received upon vesting of a restricted stock unit award. Represents shares used to cover tax withholding upon the release of restricted stock units. The sale was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.97 to $5.02, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023. Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024. /s/ Todd Rosenthal, as attorney-in-fact 2024-04-02